Literature DB >> 28920188

Lung cancer incidence and mortality in China, 2009.

Wanqing Chen1, Rongshou Zheng1, Siwei Zhang1, Xiaonong Zou1, Ping Zhao1, Jie He1.   

Abstract

BACKGROUND: The National Central Cancer Registry (NCCR) is a governmental organization for cancer surveillance affiliated to the Bureau of Disease Control, Ministry of Health, in China. It annually collects cancer registration data from local registries and then analyzes and publishes the results to provide useful information for making anti-cancer policy, program evaluation, and etiology research. At the end of 2012, the NCCR reported cancer statistics for 2009.
METHODS: By mid 2012, 104 population-based cancer registries reported cancer incidence and mortality data, including demographic information, for 2009, to the NCCR. After an evaluation procedure, a total of 72 registries' data met the criteria, which was then compiled for analysis. Individual lung cancer cases were retrieved from the national database based on the International Classification of Diseases (ICD)-10 topography code as "C33, C34," including cancers of the trachea and bronchus. The crude incidence and mortality rates of lung cancer were calculated by gender, age, and location (urban/rural). China's population in 1982 and Segi's population structures were used for age-standardized rates.
RESULTS: In cancer registration areas in 2009, lung cancer was the most common cancer in China and in urban areas, the second most common cancer in rural areas. It was the leading cause of cancer death both in males and females, urban and rural areas. The incidence and mortality rates of lung cancer were higher in males than those in females, and in urban areas than in rural areas. The age-specific incidence and mortality rates showed that both rates were relatively low for those aged under 50 years, but dramatically increased and reached a peak in the age group of 80-84 years.
CONCLUSION: Lung cancer is the most common cancer in China and leading cause of cancer death. Primary and secondary prevention should be carried out in each group, such as tobacco control and early detection.
© 2012 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cancer registry; epidemiology; incidence; lung cancer; mortality

Year:  2013        PMID: 28920188     DOI: 10.1111/1759-7714.12025

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  13 in total

1.  Bevacizumab induces A549 cell apoptosis through the mechanism of endoplasmic reticulum stress in vitro.

Authors:  Li-Le Wang; Rui-Cheng Hu; Ai-Guo Dai; Shuang-Xiang Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.

Authors:  Guanghui Gao; Keyi Jia; Sha Zhao; Xuefei Li; Chao Zhao; Tao Jiang; Chunxia Su; Shengxiang Ren; Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules.

Authors:  Yayi He; Shengxiang Ren; Yan Wang; Xuefei Li; Caicun Zhou; Fred R Hirsch
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.

Authors:  Yu Yang; Haineng Xu; Weidan Huang; Miao Ding; Jing Xiao; Dongmei Yang; Huaguang Li; Xin-Yuan Liu; Liang Chu
Journal:  J Cell Mol Med       Date:  2015-02-16       Impact factor: 5.310

5.  CLPTM1L genetic polymorphisms and interaction with smoking and alcohol drinking in lung cancer risk: a case-control study in the Han population from northwest China.

Authors:  Xiaojie Xun; Huijuan Wang; Hua Yang; Hong Wang; Bo Wang; Longli Kang; Tianbo Jin; Chao Chen
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

6.  Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer.

Authors:  Shujun Li; Xuebo Qin; Xin Guo; Airong Cui; Yuzheng He; Sen Wei; Xiaolu Wang; Baoen Shan
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 7.  [Advance of lung cancer screening with low-dose spiral CT].

Authors:  Guanhua Ren; Yaguang Fan; Yongcheng Zhao; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-10-20

8.  T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

Authors:  Keyi Jia; Yayi He; Rafal Dziadziuszko; Sha Zhao; Xiaoshen Zhang; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou; Hui Yu; Liping Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-12

9.  [Survey and analysis of awareness of lung cancer prevention and control in a LDCT lung cancer screening project in Tianjin Dagang Oilfield of China].

Authors:  Guanhua Ren; Jianfei Ye; Yaguang Fan; Jing Wang; Zhijuan Sun; Hui Jia; Xinxin Du; Chaohua Hou; Ying Wang; Yongcheng Zhao; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02

10.  sLAG-3 in non-small-cell lung cancer patients' serum.

Authors:  Yayi He; Yan Wang; Sha Zhao; Chao Zhao; Caicun Zhou; Fred R Hirsch
Journal:  Onco Targets Ther       Date:  2018-08-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.